Back to search

Article

Molecular biomarkers of response to sintilimab combined with lenvatinib for locally advanced hepatitis B virus-associated hepatocellular carcinoma

2024-05-15

Abstract excerpt

<title>Abstract</title> <p><bold>Background: </bold>The efficacy of combining immune checkpoint inhibitors with anti-angiogenic drugs in advanced hepatocellular carcinoma (HCC) varies, and the predictive biomarkers for this therapy remain unclear. <bold>Methods: </bold>In this single-center study in China, patients with HCC ineligible for traditional resection were administered sintilimab on day 1 of a 21-day cyc...

Topics

Open a Topic to create a Post that cites this publication.

Identifiers and source

Literature Corpus work
8365882e-863a-5c6f-8894-4f4d6b5d8d20
DOI
10.21203/rs.3.rs-4368601/v1
Open publication

Related research

Semantic proximity does not establish scientific evidence.

Click a neighbor to travelStep 1 · 12 closest
Interactive article relationship graphSelect a related publication card to move it into the centre and load its closest explainable connections. Solid lines are source-backed structured connections. Dashed lines are semantic discovery signals and are not scientific evidence.
Molecular biomarkers of response to sintilimab combined with lenvatinib for locally advanced hepatitis B virus-associated hepatocellular carcinomaDOI 10.21203/rs.3.rs-4368601/v1
Differential T-cell and monocyte responses in hepatocellular carcinoma treated with regorafenib plus nivolumab: an integrated clinical and biomarker analysis of the phase 2 RENOBATE trialSemantic proximity
Multi-omics analysis reveals the role of tumor-infiltrating CD4+CCR7+ T cells in EGFR antibody resistance and prognosis of hepatocellular carcinomaSemantic proximity
Lenvatinib recruits cytotoxic GZMK+CD8 T cells in hepatocellular carcinomaSemantic proximity
Exploration of Practical Biomarkers for Systemic Drug Therapy for Hepatocellular CarcinomaSemantic proximity
Notable-HCC: A phase Ib trial of neoadjuvant tislelizumab with stereotactic body radiotherapy in patients with early stage resectable hepatocellular carcinomaSemantic proximity
Advancing precision medicine in hepatocellular carcinoma: current challenges and future directions in liquid biopsy, immune microenvironment, single nucleotide polymorphisms, and conversion therapySemantic proximity
Prognostic value of the ratio of Interleukin-2 and Interleukin-10 in patients with hepatocellular carcinoma treated with anti-PD-1 therapySemantic proximity
Gut microbiota as a prognostic biomarker for unresectable hepatocellular carcinoma treated with anti-PD-1 therapySemantic proximity
Safety and efficacy of immune checkpoint inhibitors in nasopharyngeal carcinoma patients with chronic hepatitis B virus infectionSemantic proximity
Sintilimab plus irinotecan, leucovorin and 5-fluorouracil (FOLFIRI) as salvage treatment for patients with advanced gastric cancer: real-world evidence from a single-centre cohortSemantic proximity
High expression of fibroblast activation protein in hepatocellular carcinoma: characteristics of angiogenesis and immune infiltrationSemantic proximity
Exploring the impact of Durvalumab on biliary tract cancer- insights from real world clinical dataSemantic proximity
Select a neighboring publication to make it the new centre.